1. Home
  2. MIST vs SRBK Comparison

MIST vs SRBK Comparison

Compare MIST & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • SRBK
  • Stock Information
  • Founded
  • MIST 2003
  • SRBK 1887
  • Country
  • MIST Canada
  • SRBK United States
  • Employees
  • MIST N/A
  • SRBK N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • SRBK
  • Sector
  • MIST Health Care
  • SRBK
  • Exchange
  • MIST Nasdaq
  • SRBK Nasdaq
  • Market Cap
  • MIST 89.8M
  • SRBK 117.4M
  • IPO Year
  • MIST N/A
  • SRBK N/A
  • Fundamental
  • Price
  • MIST $1.94
  • SRBK $13.51
  • Analyst Decision
  • MIST Strong Buy
  • SRBK
  • Analyst Count
  • MIST 2
  • SRBK 0
  • Target Price
  • MIST $7.50
  • SRBK N/A
  • AVG Volume (30 Days)
  • MIST 566.2K
  • SRBK 122.3K
  • Earning Date
  • MIST 08-07-2025
  • SRBK 07-25-2025
  • Dividend Yield
  • MIST N/A
  • SRBK 1.48%
  • EPS Growth
  • MIST N/A
  • SRBK N/A
  • EPS
  • MIST N/A
  • SRBK N/A
  • Revenue
  • MIST N/A
  • SRBK $27,988,000.00
  • Revenue This Year
  • MIST N/A
  • SRBK N/A
  • Revenue Next Year
  • MIST N/A
  • SRBK N/A
  • P/E Ratio
  • MIST N/A
  • SRBK N/A
  • Revenue Growth
  • MIST N/A
  • SRBK 23.80
  • 52 Week Low
  • MIST $0.63
  • SRBK $9.12
  • 52 Week High
  • MIST $2.75
  • SRBK $13.65
  • Technical
  • Relative Strength Index (RSI)
  • MIST 65.73
  • SRBK 62.32
  • Support Level
  • MIST $1.86
  • SRBK $13.40
  • Resistance Level
  • MIST $1.97
  • SRBK $13.29
  • Average True Range (ATR)
  • MIST 0.10
  • SRBK 0.17
  • MACD
  • MIST 0.00
  • SRBK 0.04
  • Stochastic Oscillator
  • MIST 80.00
  • SRBK 95.89

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About SRBK SR Bancorp Inc. Common stock

SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.

Share on Social Networks: